effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections

evaluation of the effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections: A randomized interventional study in Imam Reza Hospital, Mashhad.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200325046859N2

Enrollment

100

Registered

2020-04-26

Start date

2020-04-22

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. Coronavirus infection, unspecified site

Interventions

Intervention 1: Intervention group: In this group, patients with moderate symptoms of COVID-19 take the two-drug diet of 200 mg Hydroxy chlorquine (Made by Amin Pharmaceutical Company) with 2 tablets

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Informed consent for inclusion in the study Age range within 18 to 65 Intial symptoms during the first 12 days Diagnosis with COVID-19 is definitive Moderate symptoms of COVID-19 and need for hospitalization, SPO2<93%, pulmonary infiltration in chest radiography or CT scan and clinical judgment of a specialist

Exclusion criteria

Exclusion criteria: Pregnancy Having morbidities such as heart diseases which do not allow the use of treatment drugs History of retinopathy which does not allow the use of Hydroxy chlorquine. Patient with severe condition who will not last more than 48 hours Infection with HIV

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Before and after treatment. Method of measurement: Thermometer.;Respiration rate. Timepoint: Before and after treatment. Method of measurement: Counting the number of breaths patients take per minute.;Findings of chest CT scan. Timepoint: Before and after treatment. Method of measurement: CT scan machine.;Pulse. Timepoint: Before, during and after treatment. Method of measurement: Patient monitoring device.;SpO2. Timepoint: Before and after treatment. Method of measurement: Patient monitoring device.;WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Lactate dehydrogenase. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;C reactive protein (CRP). Timepoint: Before and after treatment. Method of measurement: Biochemical test.	—

Measure

Time frame

Fever. Timepoint: Before and after treatment. Method of measurement: Thermometer.;Respiration rate. Timepoint: Before and after treatment. Method of measurement: Counting the number of breaths patients take per minute.;Findings of chest CT scan. Timepoint: Before and after treatment. Method of measurement: CT scan machine.;Pulse. Timepoint: Before, during and after treatment. Method of measurement: Patient monitoring device.;SpO2. Timepoint: Before and after treatment. Method of measurement: Patient monitoring device.;WBC. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Number of lymphocytes. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;Lactate dehydrogenase. Timepoint: Before and after treatment. Method of measurement: Biochemical test.;C reactive protein (CRP). Timepoint: Before and after treatment. Method of measurement: Biochemical test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRozita Khodashahi

Mashhad University of Medical Sciences

khodashahir@mums.ac.ir+98 51 385022406

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026